Personal information

Verified email domains

Nanomedicine, Pharmacokinetics, Oncology, Pharmacometrics, Liposomes, Immunotherapy

Biography

Anne Rodallec obtained her pharmaceutical degree and Ph.D in pharmacokinetics and oncology under the supervision at the pharmacy school of Aix-Marseille University, France. She is now an assistant teacher at the same faculty and her work focuses on the development of liposomes and immunoliposomes in cancer, from their formulation to the in vivo assays. She is currently evaluating the interest of combining these liposomes to immunotherapy and developing biomathematic models to determine the best treatment regimen.

Activities

Employment (1)

Université d'Aix-Marseille: Marseille, FR

2020-09-01 to present | Assistant professor (Pharmacokinetics)
Employment
Source: Self-asserted source
Anne Rodallec

Education and qualifications (2)

Aix-Marseille University: Marseille, FR

2015-11-01 to 2018-10-26 | Ph.D in Oncology (Advanced drug delivery)
Education
Source: Self-asserted source
Anne Rodallec

Aix-Marseille University: Marseille, FR

2009 to 2015 | Pharm. D (Pharmacy)
Education
Source: Self-asserted source
Anne Rodallec

Professional activities (1)

Controlled Release Society BeNeLux & France Local Chapter: marseille, FR

2019 to present | Website coordinator and organizing committe (Early Career Scientist)
Service
Source: Self-asserted source
Anne Rodallec

Funding (5)

COMPLICITY

2023-09 to 2024-08 | Award
Fondation ARC pour la Recherche sur le Cancer (Villejuif, FR)
Source: Self-asserted source
Anne Rodallec

COMPLICITY

2023-09 to 2023-12 | Award
DAAD (Bonn, DE)
Source: Self-asserted source
Anne Rodallec

COMPLICITY

2023-01 to 2025-03 | Grant
Amidex (Marseille, FR)
Source: Self-asserted source
Anne Rodallec

NaonoImmuno

2020 to 2022 | Grant
Institut Roche (Boulogne Billancourt, FR)
Source: Self-asserted source
Anne Rodallec

Development of a docetaxel-trastuzumab immunoliposome in breast cancer

2015 to 2018 | Contract
Ligue Contre le Cancer (Paris, FR)
Source: Self-asserted source
Anne Rodallec

Works (19)

Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models

International Journal of Pharmaceutics
2024-05 | Journal article
Contributors: Mathilde Dacos; Benoît Immordino; Erwan Diroff; Guillaume Sicard; Artemis Kosta; Anne Rodallec; Sarah Giacometti; Joseph Ciccolini; Raphaëlle Fanciullino
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors

Chemical Science
2023 | Journal article
Contributors: Patricia Piris; Duje Buric; Toshihide Yamasaki; Paul Huchedé; Maïlys Rossi; Mélanie Matteudi; Marie-Pierre Montero; Anne Rodallec; Romain Appay; Christine Roux et al.
Source: Self-asserted source
Anne Rodallec via HAL

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Pharmaceutics
2022-10-28 | Journal article
Part of ISSN: 1999-4923
Contributors: Elise Timon-David; Carla Perez; Anne Rodallec
Source: Self-asserted source
Anne Rodallec

Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic

PLOS ONE
2022-09-30 | Journal article
Contributors: Anne Rodallec; Eugene Demidenko; Cristina Vaghi; Joseph Ciccolini; Raphaelle Fanciullino; Sebastien Benzekry
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer

Pharmaceutics
2020-11-29 | Journal article
Part of ISSN: 1999-4923
Contributors: Guillaume Sicard; Clément Paris; Sarah Giacometti; Anne Rodallec; Joseph Ciccolini; Palma Rocchi; Raphaëlle Fanciullino
Source: Self-asserted source
Anne Rodallec

Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)

Anti-Cancer Drugs
2020-06 | Journal article
Part of ISSN: 0959-4973
Contributors: Anne Rodallec; Guillaume Sicard; Sarah Giacometti; Manon Carre; Thomas Maia; Margaux Valette; Fanny Bouquet; Ariel Savina; Bruno Lacarelle; Joseph Ciccolini et al.
Source: Self-asserted source
Anne Rodallec

Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles

Scientific Reports
2020-03-05 | Journal article
Part of ISSN: 2045-2322
Contributors: A. Rodallec; C. Franco; S. Robert; G. Sicard; S. Giacometti; B. Lacarelle; F. Bouquet; A. Savina; R. Lacroix; F. Dignat-George et al.
Source: Self-asserted source
Anne Rodallec

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors

PLOS Computational Biology
2020-02-25 | Journal article
Part of ISSN: 1553-7358
Contributors: Cristina Vaghi; Anne Rodallec; Raphaëlle Fanciullino; Joseph Ciccolini; Jonathan Mochel; Michalis Mastri; Clair Poignard; John Ebos; Sébastien Benzekry
Source: Self-asserted source
Anne Rodallec

Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

Anticancer Research
2019-07 | Journal article
Part of ISSN: 0250-7005
Part of ISSN: 1791-7530
Contributors: ANNE RODALLEC; RAPHAELLE FANCIULLINO; SEBASTIEN BENZEKRY; JOSEPH CICCOLINI; on Behalf of the EORTC PAMM Group
Source: Self-asserted source
Anne Rodallec

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

International Journal of Nanomedicine
2018-10 | Journal article
Part of ISSN: 1178-2013
Contributors: Anne Rodallec; Guillaume Sicard; Sarah Giacometti; Manon Carré; Bertrand Pourroy; Fanny Bouquet; Ariel Savina; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Source: Self-asserted source
Anne Rodallec

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

Expert Opinion on Drug Metabolism & Toxicology
2018-10-24 | Journal article
Part of ISSN: 1742-5255
Part of ISSN: 1744-7607
Contributors: Anne Rodallec; Guillaume Sicard; Raphaelle Fanciullino; Sébastien Benzekry; Bruno Lacarelle; Gerard Milano; Joseph Ciccolini
Source: Self-asserted source
Anne Rodallec

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology

Critical Reviews in Oncology/Hematology
2018-09 | Journal article
Part of ISSN: 1040-8428
Contributors: Anne Rodallec; Sébastien Benzekry; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Source: Self-asserted source
Anne Rodallec

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

International Journal of Nanomedicine
2018-06 | Journal article
Part of ISSN: 1178-2013
Contributors: Anne Rodallec; Jean-Michel Brunel; Sarah Giacometti; Helene Maccario; Florian Correard; Eric Mas; Caroline Orneto; Ariel Savina; Fanny Bouquet; Bruno Lacarelle et al.
Source: Self-asserted source
Anne Rodallec

Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles

Expert Review of Clinical Pharmacology
2018-06-03 | Journal article
Part of ISSN: 1751-2433
Part of ISSN: 1751-2441
Contributors: Anne Rodallec; Raphaelle Fanciullino; Bruno Lacarelle; Joseph Ciccolini
Source: Self-asserted source
Anne Rodallec

Claramines: A New Class Of Broad‐Spectrum Antimicrobial Agents With Bimodal Activity

ChemMedChem
2018-05-23 | Journal article
Part of ISSN: 1860-7179
Part of ISSN: 1860-7187
Contributors: Marine Blanchet; Diane Borselli; Anne Rodallec; Franck Peiretti; Nicolas Vidal; Jean‐Michel Bolla; Carole Digiorgio; Kelly R. Morrison; William M. Wuest; Jean Michel Brunel
Source: Self-asserted source
Anne Rodallec

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

PLOS Medicine
2018-03-27 | Journal article
Part of ISSN: 1549-1676
Contributors: Jeremie guedj; Géraldine Piorkowski; Frédéric Jacquot; Vincent Madelain; Thi Huyen Tram Nguyen; Anne Rodallec; Stephan Günther; Caroline Carbonnelle; france Mentré; Hervé Raoul et al.
Source: Self-asserted source
Anne Rodallec

Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?

Clinical Cancer Drugs
2018-01-09 | Journal article
Part of ISSN: 2212-697X
Contributors: Manon Launay; Joseph Ciccolini; Anne Rodallec; Claire Fournel; Florence Duffaud; Sebastien Salas; Bruno Lacarelle
Source: Self-asserted source
Anne Rodallec

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

PLOS Neglected Tropical Diseases
2017-02-23 | Journal article
Part of ISSN: 1935-2735
Contributors: Thi Huyen Tram Nguyen; Jeremie guedj; Xavier Anglaret; Cédric LAOUENAN; Vincent Madelain; Anne-Marie Taburet; Sylvain Baize; Daouda Sissoko; Boris Pastorino; Anne Rodallec et al.
Source: Self-asserted source
Anne Rodallec

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase‐driven adaptive dosing of 5‐FU in patients with digestive cancer

British Journal of Clinical Pharmacology
2016-01 | Journal article
Part of ISSN: 0306-5251
Part of ISSN: 1365-2125
Contributors: Manon Launay; Laetitia Dahan; Manon Duval; Anne Rodallec; Gérard Milano; Muriel Duluc; Bruno Lacarelle; Joseph Ciccolini; Jean‐Francois Seitz
Source: Self-asserted source
Anne Rodallec

Peer review (1 review for 1 publication/grant)

Review activity for Cancer chemotherapy and pharmacology. (1)